GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Cyclically Adjusted PB Ratio

ANI Pharmaceuticals (FRA:BSFA) Cyclically Adjusted PB Ratio : 2.73 (As of Jun. 02, 2025)


View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-06-02), ANI Pharmaceuticals's current share price is €50.00. ANI Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €18.33. ANI Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.73.

The historical rank and industry rank for ANI Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:BSFA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.59   Med: 3.11   Max: 6.68
Current: 2.95

During the past years, ANI Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 6.68. The lowest was 1.59. And the median was 3.11.

FRA:BSFA's Cyclically Adjusted PB Ratio is ranked worse than
66.09% of 693 companies
in the Drug Manufacturers industry
Industry Median: 1.94 vs FRA:BSFA: 2.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ANI Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was €17.876. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €18.33 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


ANI Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ANI Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Cyclically Adjusted PB Ratio Chart

ANI Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.17 3.13 2.46 3.01 2.81

ANI Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 3.30 3.05 2.81 3.36

Competitive Comparison of ANI Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

ANI Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ANI Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=50.00/18.33
=2.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, ANI Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=17.876/134.9266*134.9266
=17.876

Current CPI (Mar. 2025) = 134.9266.

ANI Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 11.645 100.684 15.605
201509 12.090 100.392 16.249
201512 12.781 99.792 17.281
201603 12.557 100.470 16.863
201606 12.659 101.688 16.797
201609 12.990 101.861 17.207
201612 13.877 101.863 18.381
201703 13.833 102.862 18.145
201706 13.501 103.349 17.626
201709 13.173 104.136 17.068
201712 12.674 104.011 16.441
201803 12.425 105.290 15.922
201806 13.409 106.317 17.017
201809 13.923 106.507 17.638
201812 14.631 105.998 18.624
201903 14.702 107.251 18.496
201906 15.221 108.070 19.004
201909 16.024 108.329 19.958
201912 15.841 108.420 19.714
202003 15.066 108.902 18.666
202006 13.789 108.767 17.105
202009 13.414 109.815 16.481
202012 13.021 109.897 15.987
202103 13.427 111.754 16.211
202106 12.497 114.631 14.710
202109 12.769 115.734 14.886
202112 17.558 117.630 20.140
202203 16.909 121.301 18.808
202206 16.942 125.017 18.285
202209 18.030 125.227 19.427
202212 16.927 125.222 18.239
202303 16.333 127.348 17.305
202306 18.637 128.729 19.534
202309 19.750 129.860 20.521
202312 19.389 129.419 20.214
202403 19.819 131.776 20.293
202406 20.101 132.554 20.461
202409 17.359 133.029 17.607
202412 18.264 133.157 18.507
202503 17.876 134.927 17.876

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ANI Pharmaceuticals  (FRA:BSFA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ANI Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines